Brian Stuglik Sells Shares of PBYI

On June 12, 2026, Brian Stuglik sold 8,100 shares of PBYI at an average price of $7.20 per share. This transaction was valued at $58,320 and was part of a planned sale under Rule 10b5-1. PBYI shares were trading at around $7.33 at the time.

Insider Buying and Selling at Puma Biotechnology, Inc.

Several insiders at PBYI engaged in stock transactions on June 12, 2026. Alongside Brian Stuglik, other insiders like Dorval Allison and Adrian Senderowicz also sold shares, each disposing of 11,610 and 27,000 shares respectively, at an average price of $7.20. Jay Moyes sold 22,000 shares at $7.22, while Troy Edward Wilson sold 10,800 shares at $7.20. These sales were planned transactions.

Other Institutional Activity in PBYI

Institutional investors have shown varied activity in PBYI. Acorn Capital Advisors maintained its position with 4,131,299 shares valued at about $26.4 million. BlackRock trimmed its holdings by 43,636 shares, ending with 3,598,952 shares worth approximately $23 million. Meanwhile, Acadian Asset Management increased its stake by 16,936 shares to hold 2,041,759 shares valued at $13 million. Renaissance Technologies reduced its position by 181,400 shares, now holding 1,942,413 shares valued at $12.4 million. American Century Companies added 266,209 shares, bringing its total to 1,916,346 shares worth about $12.2 million.

Analysts Set New Price Targets

Analysts have maintained their outlook on PBYI. On February 28, 2025, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $7.00. TD Cowen maintained a 'hold' rating with a $4.00 target on May 20, 2024, while Barclays maintained a 'sell' rating with a $2.00 target on May 3, 2024. The consensus among analysts is cautious, with varied ratings reflecting differing expectations.

Bottom Line

Brian Stuglik's planned sale of PBYI shares highlights ongoing insider activity. While insider transactions can provide insight, they are not definitive signals of future performance. Investors often track these moves as part of a broader analysis. Institutional and analyst perspectives remain mixed, indicating diverse views on PBYI's potential. As always, it's important to remember that 13F filings and insider transactions are backward-looking and don't necessarily reflect the current market position.